secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000899923-24-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05
--------------------------------------------------------------------------------

- Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).
- Raises FY2024 revenue guidance to $835-$845M (11-12% growth); adj EPS to $0.08-$0.12.
- Prenatal rev +25%, Pharmacogenomics +22%, Hereditary Cancer +19%; Tumor profiling -9% YoY.
- Cross-license with Personalis (PSNL) for MRD patents; GSK collaboration for HRD testing.
- Long-term revenue growth target raised to 12% from prior; total test volume +9% to 389K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000036/0000899923-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000036/mygn-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer